Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ)
 
 • Company Description   
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.

Number of Employees: 143

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.70 Daily Weekly Monthly
20 Day Moving Average: 1,674,281 shares
Shares Outstanding: 295.18 (millions)
Market Capitalization: $501.81 (millions)
Beta: 1.78
52 Week High: $2.17
52 Week Low: $0.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 10.39% 7.08%
12 Week 18.06% 2.34%
Year To Date 51.79% 43.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
20374 Seneca Meadows Parkway
-
Germantown,MD 20876
USA
ph: 301-556-9900
fax: -
investors@precigen.com http://www.precigen.com
 
 • General Corporate Information   
Officers
Helen Sabzevari - Chief Executive Officer
Randal J. Kirk - Executive Chairman
Harry Thomasian Jr. - Chief Financial Officer
Nancy H. Agee - Director
Cesar L. Alvarez - Director

Peer Information
Precigen, Inc. (CORR.)
Precigen, Inc. (RSPI)
Precigen, Inc. (CGXP)
Precigen, Inc. (BGEN)
Precigen, Inc. (GTBP)
Precigen, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74017N105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 295.18
Most Recent Split Date: (:1)
Beta: 1.78
Market Capitalization: $501.81 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.21 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 119.45
EPS Growth
vs. Year Ago Period: 30.00%
vs. Previous Quarter: -75.00%
Sales Growth
vs. Year Ago Period: 25.92%
vs. Previous Quarter: 12.69%
ROE
06/30/25 - -
03/31/25 - -279.20
12/31/24 - -150.24
ROA
06/30/25 - -
03/31/25 - -79.74
12/31/24 - -80.52
Current Ratio
06/30/25 - -
03/31/25 - 3.53
12/31/24 - 4.76
Quick Ratio
06/30/25 - -
03/31/25 - 3.53
12/31/24 - 4.76
Operating Margin
06/30/25 - -
03/31/25 - -2,043.66
12/31/24 - -2,240.00
Net Margin
06/30/25 - -
03/31/25 - -3,728.87
12/31/24 - -3,216.18
Pre-Tax Margin
06/30/25 - -
03/31/25 - -3,770.86
12/31/24 - -3,261.86
Book Value
06/30/25 - -
03/31/25 - -0.05
12/31/24 - 0.13
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©